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Background: Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as
second-line treatment after the failure of metformin. However, SUs are associated with poor durability,
hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development
for the treatment of T2DM. In Phase II/III trials, empagliflozin reduced hyperglycemia, body weight and blood
pressure, with a low incidence of hypoglycemia. The aim of this Phase III study is to compare the effects of
empagliflozin and the SU glimepiride as second-line therapy in patients with T2DM inadequately controlled with
metformin immediate release (IR) and diet/exercise.
Method: After a 2-week placebo run-in, patients were randomized to receive empagliflozin 25 mg once daily (qd) or
glimepiride 1–4 mg qd double-blind for 2 years, in addition to metformin IR. Patients who participate in the initial 2-
year randomization period will be eligible for a 2-year double-blind extension. The primary endpoint is change from
baseline in HbA1c. Secondary endpoints are change from baseline in body weight, the incidence of confirmed
hypoglycemia and changes in systolic and diastolic blood pressure. Exploratory endpoints include markers of insulin
secretion, body composition and responder analyses. Safety endpoints include the incidence of adverse events (AEs)
(including macro- and microvascular adverse events) and changes from baseline in clinical laboratory parameters.
Results: Between August 2010 and June 2011, 1549 patients were randomized and 1545 patients were treated. At
baseline, mean (SD) age was 55.9 (10.4) years, HbA1c was 7.92 (0.84)%, body mass index was 30.11 (5.59) kg/m
2, systolic
blood pressure was 133.5 (15.9) mmHg and diastolic blood pressure was 79.5 (9.4) mmHg.
Discussion: This is the largest study to compare the efficacy and safety of an SGLT2 inhibitor with an SU in patients
with T2DM inadequately controlled on metformin to date. In addition to determining the effects of these treatments
on glycemic control over the long term, this study will investigate effects on beta-cell function, cardiovascular risk
factors and markers of renal function/damage. The results will help to inform the choice of second-line treatment in
patients with T2DM who have failed on metformin.
Trial registration: Clinicaltrials.gov NCT01167881.
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Type 2 diabetes mellitus (T2DM) is a chronic disease
that results from a combination of insulin resistance and
insulin deficiency caused by progressive beta-cell failure
[1]. Treatment of T2DM should aim to control glycemia
to preserve quality of life and reduce the risk of the
microvascular and macrovascular complications of dia-
betes [2]. Metformin, the most commonly used anti-
diabetes agent, is recommended as first-line therapy for
patients with T2DM [2,3]. However, as glycemic control
deteriorates, patients with T2DM usually require more
than one anti-diabetes agent to control glycemia [4-6].
Sulfonylureas (SUs) are one of the treatment options
recommended for second-line therapy of T2DM [2,3]
and are commonly used in clinical practice [1,7], usually
in combination with metformin.
Sulfonylureas in the treatment of T2DM
Although initially effective in controlling hyperglycemia,
SUs have low durability [1,2]. In the UK Prospective Dia-
betes Study (UKPDS), following an initial decline in
glycosylated hemoglobin (HbA1c) in patients randomized
to receive chlorpropamide or glibenclamide compared
with patients who received dietary advice alone, a pro-
gressive increase in HbA1c was observed over the next
15 years, similar to the increase that occurred in patients
randomized to dietary advice alone [6]. Secondary failure
rates with SUs may exceed those of other anti-diabetes
agents, possibly due to increased loss of beta-cell func-
tion [1,8]. In the UKPDS, beta-cell function assessed
using the homeostasis model assessment (HOMA-B)
was found to be inversely proportional to failure rates
with SUs [9]. In a study in newly diagnosed patients with
T2DM, patients treated with an SU for up to 6 years
showed a lower C-peptide response to glucagon than pa-
tients treated with insulin, suggesting a more rapid de-
terioration in beta-cell function and endogenous insulin
production [10-12]. In a study of patients diagnosed with
T2DM for more than 3 years, the duration of SU treat-
ment was the only factor found to be independently as-
sociated with decreases in fasting C-peptide levels [13].
In addition to low durability, SUs are commonly associ-
ated with weight gain and hypoglycemia [2,14]. In patients
with T2DM receiving oral anti-diabetes agents, both
weight gain and hypoglycemia are independently associ-
ated with lower treatment satisfaction and lower health-
related quality of life [15]. Hypoglycemic episodes lead to
fear of further episodes, which may lead to patients eating
more to avoid their blood glucose becoming too low,
resulting in an association between hypoglycemia, fear of
hypoglycemia and weight gain [15]. The magnitude of im-
pact on quality of life has been observed to increase with
the severity and frequency of hypoglycemic events experi-
enced over a 6-month period [14] and the level of weightgain over 12 months [15]. Hypoglycemia and weight gain
can also affect adherence to treatment. In a cross-sectional
survey of 407 patients with T2DM, a potential weight gain
of 2.3 kg over 6 months with a fictional anti-diabetes agent
was associated with a 10-15% decreased likelihood of ad-
herence compared with an agent that caused no weight
gain; more than 2 episodes of mild-to-moderate hypogly-
cemia per month was also associated with a reduced likeli-
hood of adherence [16]. This is important, given that
adherence to medication for the treatment of T2DM is poor.
In prospective studies in patients with T2DM, rates of ad-
herence to oral anti-diabetes agents, defined as the propor-
tion of doses taken as prescribed, have been reported to be
as low as 38% [17]. Furthermore, in patients with T2DM,
non-adherence to prescribed medication has been inde-
pendently associated with all-cause mortality [18]. In the
ACCORD study, which investigated the effect of intensive
versus standard glycemic control on cardiovascular (CV)
events in patients with T2DM at high CV risk, symp-
tomatic severe hypoglycemia was associated with in-
creased all-cause mortality [19]. The mechanisms by
which hypoglycemia could precipitate a major vascular
event include autonomic activation, primarily of the
sympatho-adrenal system, provoking hemodynamic changes,
such as increased heart rate and systolic blood pressure,
increased myocardial contractility, stroke volume and car-
diac output, to maintain glucose supply to the brain [20].
Microvascular complications such as albuminuria and
decreasing estimated glomerular filtration rate (eGFR)
are independently and continuously associated with an
increased risk of CV events (CV death, non-fatal myo-
cardial infarction, stroke) and renal events in patients
with T2DM [21]. There is limited evidence that SUs re-
duce the microvascular complications of T2DM [6,22],
but the evidence is not conclusive. In the UKPDS, after
a median follow-up of 10 years, an absolute reduction of
2.8% in the incidence of microvascular endpoints was
observed in patients who were randomized to intensive
glucose control with an SU or insulin compared with pa-
tients randomized to dietary advice alone [6]. However,
most of this benefit was attributed to a reduction in ret-
inopathy requiring photocoagulation (absolute reduction
of 3.1%). Differences were detected in progression of ret-
inopathy, microalbuminuria, and albuminuria in favor of
SU/insulin, but there were no differences in blindness,
visual acuity, or renal failure [6]. This may have been be-
cause these patients were at an early stage of diabetes
and so had a low risk of such complications. During the
post-trial follow-up (median duration: 8.5 years), the re-
duced risk of microvascular events was maintained in
patients who received SU/insulin compared to dietary
advice alone, despite there being no difference between
the groups in HbA1c after 1 year [23]. In the ADVANCE
study in patients with T2DM and a high risk of vascular
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gliclazide reduced the absolute incidence of microvascu-
lar complications compared with standard glucose con-
trol by 1.5% over a median follow-up of 5 years, a
reduction that was primarily due to a reduction in new-
onset microalbuminuria [22].
Most patients with T2DM die from CV-related causes
[24]. The effect of SUs on macrovascular disease is un-
clear. In the UKPDS, intensive glucose control with SU/
insulin was not associated with a reduction in macro-
vascular complications compared with dietary advice
after a median follow-up of 10 years [6]. However, after
a median follow-up of 16.8 years, significant reductions
in myocardial infarction (by 15%), diabetes-related death
(by 17%) and all-cause mortality (by 13%) were observed
in patients randomized to receive SU/insulin compared
with dietary advice alone during the intervention part of
the study [23]. In the ADVANCE study, intensive glu-
cose control provided by gliclazide did not reduce the
risk of major macrovascular events in high-risk patients
over a median follow-up of 5 years compared with
standard glucose control [22], while in a retrospective
cohort study in 5795 patients with T2DM, all-cause
mortality was higher in patients receiving monotherapy
with higher daily doses of first-generation SUs (adjusted
hazard ratio [HR] 2.1) or glibenclamide (adjusted HR
1.3) than in patients receiving lower doses, as was mor-
tality due to acute ischemic events (adjusted HR 1.2 and
1.4, respectively) [25]. A recent review of randomized
controlled trials that evaluated the impact of SUs on CV
outcomes found no increase in the incidence of CV
events with SUs, but noted that the available data are
limited and there have been no adequately powered tri-
als addressing the CV safety of SUs [26].
Empagliflozin, an SGLT2 inhibitor
Empagliflozin is a potent and selective sodium glucose
cotransporter 2 (SGLT2) inhibitor [27] in development
for the treatment of T2DM. SGLT2, found in the prox-
imal tubule of the nephron, is responsible for the re-
absorption of ~90% of the glucose filtered through the
kidneys [28]. By blocking SGLT2, empagliflozin reduces
renal glucose reabsorption, leading to excretion of glu-
cose in the urine, thus reducing hyperglycemia in pa-
tients with T2DM [29]. In Phase II and III studies,
empagliflozin improved glycemic control in patients with
T2DM when used as monotherapy [30,31] or as add-on
therapy [32-36]. In Phase III studies, treatment with
empagliflozin was also associated with mean placebo-
corrected reductions in body weight of 1.6 kg to 2.9 kg
over 24 to 78 weeks [31,33-36], likely due to the loss of
calories (glucose) in the urine. Further empagliflozin was
associated with mean placebo-corrected reductions in
systolic blood pressure of 2.1 mmHg to 4.8 mmHg over24 to 78 weeks [31,33-36]; this may be due to a mild os-
motic diuretic effect associated with urinary glucose
excretion [37].
Empagliflozin is well tolerated in patients with T2DM
[30-36,38,39]. As the mechanism of action of SGLT2 in-
hibitors is independent of the action of insulin [40,41],
empagliflozin is associated with a low risk of hypoglycemia
[30-36,38,39]. It is tempting to speculate that the insulin-
independent mechanism of action of empagliflozin may
preserve beta-cell function and provide better durability of
glycemic control than SUs. In an 8-week study in Zucker
Diabetic Fatty (ZDF) rats, an animal model of T2DM,
treatment with empagliflozin, but not with the SU gliben-
clamide, preserved beta-cell mass, increased insulin levels,
and improved glycemic control [42]. Furthermore, due to
its body weight and blood pressure lowering properties, in
addition to its effects on glycemic control, treatment with
empagliflozin may have a beneficial effect on CV risk
[43,44]. A large dedicated CV outcome study is underway
to determine the effect of empagliflozin on CV endpoints
(NCT01131676).
Empagliflozin versus glimepiride: a 4-year phase III trial
The objective of this trial, the EMPA-REG H2H-SU™
trial, is to compare the effects of the SGLT2 inhibitor
empagliflozin with the SU glimepiride given over the
long term (4 years) as second-line therapy for T2DM in
patients in whom metformin and diet/exercise has failed
with respect to 1) glycemic control, 2) beta-cell function,
3) the CV risk factors: body weight, blood pressure and
lipid levels, and 4) safety including prospectively adjudi-
cated CV events and markers of renal function/damage.
All patients have been recruited and randomized.
Blinded baseline data are presented in this manuscript.
Methods
Patients
Adults (aged ≥ 18 years) with T2DM and insufficient
glycemic control (HbA1c ≥7% and ≤10%) were eligible
for inclusion in the study if they had received an un-
changed dose of metformin immediate release (IR)
(≥1500 mg/day, or the maximum tolerated dose, or the
maximum dose according to the local label) for ≥12 weeks
prior to randomization and met the inclusion and exclu-
sion criteria listed in Table 1. All participants provided
written informed consent prior to screening.
Study design
The protocol stated that patients were to be screened for
eligibility for the study 21±7 days prior to randomization.
Eligible patients were to undergo a 2-week, open-label,
placebo run-in period prior to randomization, during
which metformin IR was to be continued at the patient’s
usual dose. Following the run-in period, patients still
Table 1 Key inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Adult (aged ≥18 years) male or female patients with T2DM with
insufficient glycemic control with diet, exercise and metformin IR*
(≥1500 mg/day or maximum tolerated dose, or maximum dose according
to local label, with dose unchanged for 12 weeks prior to randomization)
Blood glucose level >240 mg/dL (13.3 mmol/L) after an overnight fast
during placebo run-in, confirmed by a 2nd measurement
HbA1c ≥7% and ≤10% at screening Use of any anti-diabetes drugs other than metformin IR ≤12 weeks prior
to randomization
BMI ≤45 kg/m2 at screening Bariatric surgery within 2 years; treatment with anti-obesity drugs within
3 months of screening; any treatment leading to unstable body weight
Female patients: post-menopausal, or pre-menopausal and using
appropriate contraception; not pregnant/breastfeeding
eGFR <60 mL/min/1.73 m2 (MDRD) during screening or placebo run-in
Indication of liver disease (ALT, AST or alkaline phosphatase >3 x ULN)
during screening or placebo run-in
History of cancer within 5 years (except basal cell carcinoma)
Acute coronary syndrome, stroke or transient ischemic attack within
3 months of informed consent
Disorders causing unstable red blood cells; treatment with systemic
steroids; change in dose of thyroid hormones within 6 weeks of
screening; any uncontrolled endocrine condition (except T2DM)
Alcohol or drug abuse within 3 months of informed consent
Taking an investigational drug ≤ 30 days prior to receiving study drug
Legend: T2DM type 2 diabetes mellitus, IR immediate release, HbA1c glycosylated hemoglobin, BMI body mass index, eGFR estimated glomerular filtration rate,
MDRD Modified Diet Renal Disease formula, ALT alanine transaminase, AST aspartate transaminase, ULN upper limit of normal.
*One patient took metformin extended release.
Figure 1 Study design. *Glimepiride was initiated at 1 mg/day, with
the recommendation to uptitrate if fasting plasma glucose levels
(assessed by home monitoring) were >110 mg/dL, to 2 mg/day at
week 4, to 3 mg/day at week 8, and to a maximum of 4 mg/day at
week 12. Uptitration can be withheld if it would place the patient at
risk of hypoglycemia. Glimepiride dose can be downtitrated at any
time to prevent recurrent hypoglycemia.
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ceive empagliflozin 25 mg qd or glimepiride 1–4 mg qd in
a double-blind, double-dummy manner for 2 years, in
addition to metformin IR (Figure 1). Glimepiride was initi-
ated at a dose of 1 mg/day, with the recommendation for
uptitration if fasting plasma glucose (FPG) (assessed by
home monitoring) was >110 mg/dL to 2 mg/day at week
4, to 3 mg/day at week 8, and to a maximum of 4 mg/day
at week 12. Uptitration was to be withheld if it would place
the patient at risk of hypoglycemia and should not take
place after week 12. The glimepiride dose can be down-
titrated at any time to prevent recurrent hypoglycemia.
Randomization was achieved using a computer-generated
random sequence communicated via a third-party inter-
active voice or web response system. Randomization was
stratified by HbA1c at screening (<8.5% and ≥8.5%), eGFR
according to the Modified Diet Renal Disease (MDRD) for-
mula (<90 mL/min/1.73 m2 and ≥90 mL/min/1.73 m2)
and region (Europe/South Africa, Asia, North America,
and Latin America). Patients who participate in the 2-year
randomized treatment period are eligible to participate
in a 2-year extension period, during which they will
continue to receive the treatment allocated at randomi-
zation in a double-blind, double-dummy manner. All
patients will be followed up for 4 weeks after the last
dose of study drug.
Patients received diet and exercise counseling at the
beginning of the placebo run-in period based on local
recommendations. Patients will be reminded about the
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ercise plan at every study visit. Rescue therapy can be
initiated during the 4-year treatment period if a patient
has the following confirmed blood glucose levels after an
overnight fast: >240 mg/dL during weeks 1 to 12,
>200 mg/dL during weeks 12 to 28 and >180 mg/dL (or
HbA1c >8%) after week 28. The choice and dosage of
rescue medication are at the discretion of the investiga-
tor, but must not include an SU or SGLT2 inhibitor. The
use of any anti-diabetes agents other than study medica-
tion, stable background metformin IR and rescue ther-
apy is not permitted. There are no additional restrictions
on the use of concomitant medications, except for those
listed in the exclusion criteria (Table 1), which will be
monitored throughout the trial.
The Clinical Trial Protocol was approved by the rele-
vant Institutional Review Boards and local Independent
Ethics Committees and the trial was conducted in ac-
cordance with the Declaration of Helsinki and the Inter-
national Conference on Harmonization guidelines for
Good Clinical Practice.
Endpoints
Important efficacy study endpoints are listed on the next
page, and time points at which primary and key second-
ary efficacy parameters will be measured are shown in
Table 2. The primary endpoint of this study is change
from baseline in HbA1c. Confirmed hypoglycemic events
(reported as adverse events with plasma glucose
≤3.9 mmol/L and/or requiring assistance from another
person to administer carbohydrate, glucagon, or other
resuscitative actions) will be evaluated as a secondary
endpoint. Exploratory endpoints include change from
baseline in FPG, the proportion of patients achieving
HbA1c <7%, effects on various biomarkers of beta-cell
function including insulin, C-peptide, HOMA-B and
proinsulin/insulin ratio, and the annualized slope of gly-
cemic control (coefficient of durability). In one sub-Table 2 Timings of measurements of efficacy parameters
HbA1c At screening, randomization, after
4, 12, 28, 40, 52, 65, 78, 91, 104, 117,
130, 143, 156, 169, 182, 195 and 208
weeks of treatment
Body weight At screening, randomization, after 12, 28,
52, 78, 104, 130, 156, 182 and 208 weeks
of treatment, and follow-up (4 weeks after
treatment discontinuation)
Blood pressure At screening, start of placebo run-in,
randomization, after 4, 8, 12, 16, 28, 40,
52, 65, 78, 91, 104, 117, 130, 143, 156, 169,
182, 195 and 208 weeks of treatment, and
follow-up (4 weeks after treatment
discontinuation)
Legend: HbA1c glycosylated hemoglobin.study, 2-hour post-prandial glucose (PPG) and markers
of beta-cell function and insulin resistance will be
assessed in patients who undergo a mixed meal toler-
ance test (MTT) and in a separate sub-study, mean daily
glucose (MDG) will be determined based on 8-point glu-
cose profiles. To determine the 8-point glucose profile,
patients will measure their blood glucose using a home
monitoring kit at the following timepoints: after an over-
night fast, 0–5 minutes before study medication and
breakfast; 90 minutes after the start of breakfast; 0–5 mi-
nutes before lunch and dinner; 90 minutes after the start
of lunch and dinner; 0–5 minutes before bed; and again
after an overnight fast. In addition, primary, secondary
and exploratory endpoints will be evaluated in a sub-
group of patients with Latent Autoimmune Diabetes in
Adulthood (LADA), identified by the presence at baseline
of autoantibodies against insulin, islet cell cytoplasm, glu-
tamic acid decarboxylase 65 or the intracytoplasmic do-
main of the tyrosine phosphatase-like protein IA-2.
List of study efficacy endpoints
Primary efficacy endpoints
Change from baseline in HbA1c after 52 and
104 weeks of treatment
Key secondary endpoints
Change from baseline in body weight after 52 and
104 weeks of treatment
Occurrence of confirmed hypoglycemic AEs† during
52 and 104 weeks of treatment
Change from baseline in SBP and DBP after 52 and
104 weeks of treatment
Exploratory endpoints
Glucose control
HbA1c <7.0% or <6.5% after 52, 104 and 208 weeks
of treatment
HbA1c lowering by ≥0.5% after 52, 104 and
208 weeks of treatment
Change from baseline in HbA1c after 208 weeks of
treatment
Coefficient of durability for HbA1c response
‡
Change from baseline in FPG after 52, 104 and
208 weeks of treatment
Change from baseline in MDG (8-point) after 52,
104 and 208 weeks of treatment (sub-study)
Change from baseline in 2-h PPG after 52, 104 and
208 weeks of treatment and follow-up (4 weeks
after treatment discontinuation) (sub-study)
Biomarkers of insulin secretion and resistance after
104 and 208 weeks of treatment and (in the MTT
sub-study) follow-up (4 weeks after treatment
discontinuation)
Confirmed hypoglycemic AEs† during 208 weeks of
treatment
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>5% after 52, 104 and 208 weeks of treatment
Change from baseline in body weight after
208 weeks of treatment and follow-up (4 weeks
after treatment discontinuation)
Change from baseline in waist circumference after
52, 104 and 208 weeks of treatment and follow-up
(4 weeks after treatment discontinuation)
Changes from baseline in trunk fat, limb fat, fat-free
mass and total fat mass (using DXA scan) after 52,
104 and 208 weeks of treatment (sub-study)
Changes from baseline in bone mineral density and
T-scores (using DXA scan) after 52, 104 and
208 weeks of treatment (sub-study)
Changes from baseline in abdominal VAT, abdominal
SAT and VAT/SAT ratio (using MRI) after 52, 104
and 208 weeks of treatment (sub-study)
Blood pressure
Proportion of patients with BP <130/80 mmHg
after 52, 104 and 208 weeks of treatment
Change from baseline in SBP and DBP after
208 weeks of treatment and follow-up (4 weeks
after treatment discontinuation)
Composite endpoints
HbA1c <7.0% or HbA1c reduction ≥1.0%, no
confirmed hypoglycemic AEs, and weight loss >2%
after 52, 104 and 208 weeks of treatment
HbA1c <6.5% or HbA1c reduction ≥1.0%, no
confirmed hypoglycemic AEs, and weight loss >2%
after 52, 104 and 208 weeks of treatment
Lipid profile
Change from baseline in lipid profile after 52, 104
and 208 weeks of treatment and follow-up (4 weeks
after treatment discontinuation)
†Blood glucose ≤70 mg/dL and/or assistance required.
‡Calculated as slope of least-squares regression line
including all measurements from week 28 to last
available measurement.
Legend: HbA1c glycosylated hemoglobin, AEs
adverse events, SBP systolic blood pressure, DBP
diastolic blood pressure, FPG fasting plasma glucose,
MDG mean daily glucose, PPG post-prandial glucose,
MTT meal tolerance test, DXA Dual Energy X-ray
Absorptiometry,VAT visceral adipose tissue,
SAT subcutaneous adipose tissue, MRI magnetic
resonance imaging, BP: blood pressure.
Change from baseline in body weight will be evaluated
as a key secondary endpoint. Exploratory endpoints in-
clude the proportion of patients with >5% reduction in
body weight and change in waist circumference. The ef-
fects of empagliflozin and SU on body fat content anddistribution (e.g. changes in total body fat, trunk fat, ab-
dominal visceral adipose tissue and subcutaneous adipose
tissue) will be assessed in a dedicated body composition
sub-study using Dual Energy X-ray Absorptiometry
(DXA) and Magnetic Resonance Imaging (MRI) scans.
Changes from baseline in systolic and diastolic blood
pressure will be evaluated as key secondary endpoints.
Exploratory endpoints include the proportion of patients
achieving blood pressure control (<130/80 mmHg) and
effects on plasma lipids. The effect of treatment on the
composite endpoint of HbA1c <7.0% and/or a reduction
in HbA1c of ≥1.0%, with no confirmed hypoglycemic
events, and weight loss of >2% body weight, will be ex-
amined as an exploratory endpoint.
Safety endpoints include all AEs reported during the
trial; vital signs; clinical laboratory findings; prospectively
adjudicated CV events; markers of renal function/dam-
age including changes from baseline in creatinine, eGFR
and albuminuria, as well as the incidence of new-onset
albuminuria; laboratory bone markers, and, in the body
composition sub-study, changes from baseline in bone
mineral density, as determined by DXA scan.
Statistical analysis
The main analysis will be undertaken after 104 weeks of
treatment; an interim analysis is planned after 52 weeks of
treatment (Table 3). The non-inferiority of empagliflozin
compared to glimepiride on the primary endpoint of
change from baseline in HbA1c will be tested after 52 and
104 weeks of treatment based on a one-sided significance
level of 1.25%. In total, 698 patients per arm are required
to provide a power of ≥95% to show non-inferiority, based
on a margin of 0.3%, on the primary endpoint at 52 and
104 weeks at this significance level if the true treatment ef-
fect is 0.05% (adjusted for multiplicity related to the
52-week analysis), and the standard deviation is 1.2%.
The superiority of empagliflozin compared to glimepiride
on the primary endpoint will be tested after 104 weeks’
treatment. Other key secondary endpoints will be tested
for superiority at weeks 52 and 104, based on a significance
level of 2.5% (two-sided) (Table 3). All other exploratory
tests, including all analyses conducted at 208 weeks, will be
2-sided at a 5% level (no multiplicity adjustment).
The efficacy analyses will be performed on the full
analysis set (FAS), i.e. all randomized patients who re-
ceived ≥1 dose of study drug and had a baseline HbA1c
assessment, using the last observation carried forward
(LOCF) methodology for imputation of missing data. Ef-
ficacy data after the first intake of rescue medication will
be set to missing. For the primary endpoint, an analysis
of covariance (ANCOVA) model will be used with ran-
domized treatment, eGFR and geographical region as
fixed effects and baseline HbA1c as a covariate. Sensitiv-
ity analyses of the primary endpoint will be undertaken
Table 3 Hierarchical statistical methods
Analysis Testing hierarchy for 52-week analysis (interim analysis) Testing hierarchy for 104-week analysis (main analysis)
1 Primary Non-inferiority in change from baseline in HbA1c Non-inferiority in change from baseline in HbA1c
2 Secondary Superiority in change from baseline in body weight Superiority in change from baseline in body weight
3 Superiority in incidence of confirmed hypoglycemic AEs Superiority in incidence of confirmed hypoglycemic AEs
4 Superiority in change from baseline in SBP Superiority in change from baseline in HbA1c
5 Superiority in change from baseline in DBP Superiority in change from baseline in SBP
6 Superiority in change from baseline in DBP
Legend: HbA1c glycosylated hemoglobin, AEs adverse events, SBP systolic blood pressure, DBP diastolic blood pressure.
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without any important protocol violations during the
first 104 weeks’ treatment, such as violating the inclu-
sion or exclusion criteria, changing dose of background
metformin IR, taking the incorrect trial medication, or
compliance <80%), FAS104 completers (patients in the
FAS who complete the 2-year treatment period and have
HbA1c values for the end of the treatment period) and
PPS104 completers (FAS104 completers who do not
have any important protocol violations) using the same
model and the LOCF approach to missing data. Add-
itional sensitivity analyses include a restricted maximum
likelihood-based model repeated measures (MMRM) ap-
proach in observed cases in the FAS to determine the ef-
fect of empagliflozin on HbA1c over time. Secondary
endpoints will be analyzed using the same model as the
primary endpoint, with the continuous baseline values of
the endpoint being investigated included as an additional
covariate. Blood pressure data after changes in antihy-
pertensive medication will be set to missing and imputed
using LOCF.
All safety endpoints will be analyzed in the treated set,
i.e. all patients who received ≥1 dose of study drug and
presented using descriptive statistics. Confirmed hypogly-
cemic events will be analyzed using Cochran-Mantel
Haenszel tests stratified by baseline HbA1c (<8.5% vs. ≥8.5%).
Change from baseline in lipid parameters will be analyzed
using ANCOVA. Time-to-event analyses (Kaplan-Meier)
for onset of new microalbuminuria (albumin/creatinine
ratio [ACR] ≥30 mg/g), onset of new macroalbuminuria
(ACR ≥300 mg/g), and progression from microalbumi-
nuria to macroalbuminuria groups compared using log-
rank tests.
Results
Between August 2010 and June 2011, 1549 patients across
173 sites in 23 countries were randomized to receive study
drug, of whom 1545 were treated. The baseline character-
istics of the treated patients are shown in Table 4. The
mean (SD) age was 55.9 (10.4) years, the mean (SD)
HbA1c, was 7.92 (0.84)% and the mean (SD) BMI was
30.11 (5.29) kg/m2. Mean (SD) systolic blood pressure was
133.5 (15.9) mmHg and mean (SD) diastolic bloodpressure was 79.5 (9.4) mmHg, with 68.5% of patients hav-
ing uncontrolled hypertension (≥130/80 mmHg).
Discussion
This head-to-head trial aims to establish comparative ef-
fectiveness between the SGLT2 inhibitor empagliflozin
and the sulfonylurea glimepiride, used as second-line ther-
apy in patients with T2DM in whom metformin and diet/
exercise has failed, with regard to glycemic control, beta-
cell function, diabetes-associated comorbidities such as
obesity and hypertension, and safety, including macro-
and renal microvascular complications, over 4 years.
This study is the largest head-to-head trial comparing
an SGLT2 inhibitor with an SU to date [45,46]. As is typ-
ical of patients with T2DM, most of the patients in this
study were overweight or obese and the majority had
hypertension. The large number of patients enrolled in
this study will enable important sub-group analyses to be
performed, including analyses by the stratification factors
baseline HbA1c, eGFR, and region, but also analyses by
baseline HOMA-IR, HOMA-B and BMI to characterize
the efficacy of empagliflozin versus glimepiride in distinct
subpopulations. Every effort is being made to keep pa-
tients randomized in the trial, for example, by allowing
downtitration of SU to prevent recurrent hypoglycemia,
by allowing patients who take rescue medication to stay in
the trial, and by imposing very limited restrictions on con-
comitant medications. Every effort is being made to
follow-up with patients who discontinue study drug.
Durability of efficacy and preservation of beta-cell
function are important unmet medical needs in the
treatment of patients with T2DM. This study will com-
pare the effect of the insulin secretagogue glimepiride
with empagliflozin, which has an insulin-independent
mode of action, on the annualized slope of glycemic
control (coefficient of durability) and biomarkers of in-
sulin secretion over 4 years. Furthermore, the study de-
sign includes a 4-week follow-up period to assess, using
a mixed MTT, whether empagliflozin truly delays or
masks deterioration of beta-cell function during treat-
ment through urinary glucose excretion.
Identification of chronic kidney disease and its pro-
gression is based on the assessment of renal function












Europe/South Africa 639 (41.4)
Asia 434 (28.1)
Latin America 276 (17.9)
North America 196 (12.7)
Age (years), mean (SD) 55.9 (10.4)
Time (years) since diagnosis of T2DM, n (%)
≤1 172 (11.1)
>1 to 5 677 (43.8)
>5 to 10 425 (27.5)
>10 271 (17.5)
Body weight (kg), mean (SD) 82.8 (19.2)
Body mass index (kg/m2), mean (SD) 30.1 (5.3)
Body mass index (kg/m2), n (%)
<25 243 (15.7)
25 to <30 587 (38.0)
30 to <35 434 (28.1)
≥35 281 (18.2)
Waist circumference (cm), mean (SD)
Male 104.1 (13.0)
Female 98.8 (12.8)
HbA1c (%), mean (SD) 7.9 (0.8)
HbA1c (%), n (%)
<8.5 1173 (75.9)
≥8.5 372 (24.1)
Fasting plasma glucose (mg/dL), mean (SD) 149.9 (33.9)a
HOMA-IR (mU/L x mmol/L), mean (SD) 6.03 (5.31)b
HOMA-B (mU/mmol), mean (SD) 77.0 (79.0)c
Cardiovascular medications, n (%) 1174 (76.0)
Antihypertensive agents 933 (60.4)
Lipid lowering agents 805 (52.1)
Acetylsalicylic acid 498 (32.2)
Systolic blood pressure (mmHg), mean (SD) 133.5 (15.9)
Diastolic blood pressure (mmHg), mean (SD) 79.5 (9.4)
Table 4 Baseline characteristics (treated set: n=1545)
(Continued)
Blood pressure controlled (<130/80 mmHg), n (%)
Yes 486 (31.5)
No 1059 (68.5)
Serum lipids (mmol/L), mean (SD)




Markers of renal function and damage
eGFR (mL/min/1.73 m2) according to MDRD, mean (SD) 88.0 (17.3)
eGFR (mL/min/1.73 m2) according to MDRD, n (%)
≥90 (normal renal function) 633 (41.0)
60 to <90 (mild renal impairment) 877 (56.8)
30 to <60 (moderate renal impairment) 35 (2.3)
Urine albumin/creatinine ratio (mg/g), mean (SD) 40.22 (135.59)
Urine albumin/creatinine ratio (mg/g), n (%)
<30 (normal) 1221 (79.0)
30 to <300 (microalbuminuria) 289 (18.7)
≥300 (macroalbuminuria) 35 (2.3)
Legend: T2DM type 2 diabetes mellitus, HbA1c glycosylated hemoglobin,
HOMA-IR homeostasis model assessment of insulin resistance, HOMA-B
homeostasis model assessment of beta-cell function, eGFR estimated
glomerular filtration rate, MDRD Modified Diet Renal Disease formula.
an=1543; bn=1441; cn=1440; dn=1518; en=1517; fn=1516.
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dations for intensive glycemic control for prevention or
delay of diabetic nephropathy are based almost exclusively
on studies that have demonstrated an improvement in
albuminuria [47]. In patients with T2DM and chronic
kidney disease, glycemic control is recommended to be part
of a multifactorial intervention strategy that includes blood
pressure control [47]. Thus, empagliflozin, which lowers
blood pressure and body weight as well as improving
glycemic control, may offer an advantage over glimepiride
in reducing the onset or deterioration of albuminuria as a
surrogate marker of glomerular and tubular damage. A
limitation of this study is that as the incidence of doubling
of serum creatinine, end-stage renal disease or death from
renal disease is expected to be low in these patients with
normal renal function or mild renal impairment at baseline,
this study is not powered to detect differences in hard renal
outcome events.
Reduction of macrovascular complications is an import-
ant goal in the management of patients with T2DM. While
this study is not powered to detect a difference in CV
outcomes - assuming a yearly rate of 4-MACE (major ad-
verse cardiac events) (CV death, non-fatal myocardial in-
farction, non-fatal stroke, hospitalization for unstable
angina) of 1% in this low-risk population, one might expect
Ridderstråle et al. Cardiovascular Diabetology 2013, 12:129 Page 9 of 10
http://www.cardiab.com/content/12/1/129approximately 60 adjudicated 4-MACE in a 4-year trial -
exploratory comparative effectiveness data could support
treatment decisions until hard evidence emerges from
dedicated CV outcome trials.
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